In breast cancer, ER+ luminal versus TNBC subtypes exhibit distinct reliance on acetylation-regulated autophagy: luminal tumors often depend on ER–p300 signaling, whereas TNBC exploits H3K27 acetylation and DDIT4-AS1–driven autophagy to resist chemotherapy. This evidence concerns the gene EP300 and breast cancer.